Skip to main content
. 2014 Sep 17;19(10):1100–1109. doi: 10.1634/theoncologist.2014-0103

Figure 1.

Figure 1.

Fraction of patients with first-line treatment with gefitinib or erlotinib (patients with EGFR-mutated cancer) and overall rate of EGFR testing. The actual numbers of tested patients and patients diagnosed per year are also given.

Abbreviation: EGFR, epidermal growth factor receptor.